COMPANY:

Precipio

"Precipio, Inc...announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024—August 8, 2024)."

"GenomOncology, a leading provider of precision medicine software, and Precipio, a specialty cancer diagnostics company, announced their strategic partnership aimed at advancing myeloid testing and clinical genomic reporting...GenomOncology's Pathology Workbench will be utilized as the tertiary analysis and fully-customized clinical genomic reporting platform for Precipio's Next Generation Sequencing test for myeloid neoplasms. This test is integrated with Precipio's laboratory information systems, empowering their team to efficiently deliver test results to the ordering physician....Precipio needed a systematic approach to analysis and reporting and selected GenomOncology's Pathology Workbench to provide support for variant filtering and interpretation, case review, customizable reporting, and matching appropriate therapy and clinical trial options to each patient."

"Specialty cancer diagnostics company Precipio, Inc...announces it has entered into a distribution agreement with Cardinal Health for its HemeScreen molecular assay products...Under the agreement, Cardinal Health will market and distribute Precipio’s HemeScreen portfolio of molecular assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories."

"Precipio, Inc...announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market."

"...Precipio, Inc...announces the launch of its new Quantitative BCR-ABL 2.0 panel, with features making it the most innovative panel of its kind on the market...Precipio’s BCR-ABL assay can detect gene mutations as infrequent as 1 in 100,000. This is twice as sensitive as the next most sensitive qPCR assay on the market."

"Precipio, Inc. leveraged its proprietary HemeScreen Cytopenia panel as part of the diagnostic process for molecular identification of driver mutations in a patient with a history of transfusion-dependent anemia and experiencing progressive weakness and neurological symptoms. The findings point to an underlying myeloid stem cell disorder, including a myelodysplastic syndrome and possibly a higher-grade myeloid neoplasm."

"Precipio, Inc...announces that it has entered into a collaboration agreement with a NY-based academic healthcare institution to jointly develop a panel for Glioblastoma (GBM), an aggressive brain cancer based on Precipio’s HemeScreen technology."

"Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression which allowed the lab to uncover an additional oncogene isoform expression (p190)."

"Precipio, Inc...presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty at the University of Pennsylvania. The study, expected to be published in detail early next year, demonstrates the superior results of Precipio’s HemeScreen® MPN panel when compared to Sanger Sequencing (considered the 'gold standard' of molecular testing)."

"Specialty cancer diagnostics company Precipio, Inc...has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage, this distribution channel partner’s sales team will begin promoting and driving sales of the HemeScreen platform to hundreds of their current accounts."

"Precipio, Inc...announces the launch of its second generation of HemeScreen panels. Precipio’s customers using HemeScreen in their laboratory will have the option of upgrading to the 1-step assay, or remaining with the current assay...While the first generation of panels required a 2-step process that included a positive-confirmation step, the new version no longer requires this step. This means that both positive and negative results can be reached at the completion of the assay run within approximately 3 hours."

"Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers."

"Precipio, Inc...announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union. The approval was provided by the Medicines & Healthcare Products Regulatory Agency...The CE-IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification allows Precipio to market the Hemescreen reagents in the UK and the 27 countries of the European Union (EU)...The panels approved for immediate sale in the EU are the HemeScreen MPN, AML, Anemia/MDS, and CLL panels. "

"Precipio, Inc...is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College, organized by publication Dark Daily, the premier laboratory conference, held April 26th through 28th in New Orleans."

"Precipio, Inc...announces that its HemeScreen RUO assay has received the required approval from New York State’s Department of Health (NY DOH). Hemescreen can now be used by New York based physician-owned laboratories (POLs) who apply to run HemeScreen in their lab as a laboratory-developed test (LDT)."